Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19

Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has created a global pandemic infecting over 230 million people and costing millions of lives. Therapies to attenuate severe disease are desperately needed. Cenicriviroc (CVC), a C-C chemokin...

Descripción completa

Detalles Bibliográficos
Autores principales: Files, Daniel Clark, Tacke, Frank, O’Sullivan, Alexandra, Dorr, Patrick, Ferguson, William G., Powderly, William G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9231801/
https://www.ncbi.nlm.nih.gov/pubmed/35749425
http://dx.doi.org/10.1371/journal.ppat.1010547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9231801/
https://www.ncbi.nlm.nih.gov/pubmed/35749425
http://dx.doi.org/10.1371/journal.ppat.1010547

Ejemplares similares